DOCSLIB.ORG

Alexandria Real Estate Equities, Inc. 2006 Annual Report

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alexandria Real Estate Equities, Inc. 2006 Annual Report ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE:NYSE) is the largest owner and Alexandria Real pre-eminent first-in-class inter - national real estate operator focused principally on the Estate Equities, Inc. ownership, operation, redevelopment, selective development and acquisition of properties containing office 2006 Annual Report and laboratory space. Alexan - dria is the leading provider of real estate to the life science industry and has an outstand - ing almost ten-year track record as a NYSE listed company with an approximate $5.1 billion total market capi - talization as of December 31, 2006. Alexandria provides high quality real estate, techni - cal infrastructure, services, and capital to the broad and diverse life science sector. Client tenants include universities and not-for-profit institutions, pharmaceutical, biotechnology, medical device, life science product, service, biodefense and translational research entities, as well as governmental agencies. Alexandria’s international operating platform is based on the principle of “clustering” with assets and operations strategically located and dominant in each key life science cluster submarket. Total return performance reflects the performance of Alexandria Real Estate Equities, Inc., compared to NAREIT All Equity, Russell 2000 and S&P 500 indices (total return performance from IPO on May 28, 1997 to December 31, 2006, assuming the reinvestment of all dividends). “The most powerful ideas are simple, and brands adhere to the same rules. Creating simple, but powerful differentiation in the minds of your customers, your staff, indeed all of your stakeholders, requires a clear and compelling vision that is expressed in everything you do; from product to service, through environments, to the people you hire and the way you talk about yourself.” Jez Frampton, CEO , INTERBRAND BusinessWeek/Interbrand Best Global Brands 2006 The Science of Building a Dominant Brand Leader Campus of Technology Square @ MIT Cambridge, Massachusetts Pictured Right Alexandria = = Labspac e® On the eve of our tenth anniversary as a NY SE listed company, the critical components of Alexandria’s enduring success are aligned with the distinguishable characteristics that define pre-eminent international brands Knowledge of the Customer Superior Product Focused Niche Global Reach Sustainability To Fellow Alexandria Real Estate ON THE EVE of our tenth virtues and progress our anniversary as a public mission, the core of our culture Equities, Inc. Owners company, Alexandria has, once is defined by unparalleled again, posted one of the best excellence, earnest service, operational and financial cutting edge innovation, inter - performances of any REIT dependent team work, mutual since we came public in 1997. respect, responsibility, and Alexandria’s proprietary oper - unwavering integrity. At ating platform and Unique Alexandria, we define success Roadmap for Growth ® by what we do and accomplish continue to enable us to as much as who we are and provide strong, consistent, what we stand for. and predictable investment We have been able to returns for all investor styles. generate a “compounded We manage Alexandria with annual growth rate” (from our a long-term focus and are initial public offering on May convinced this is the best way 28, 1997 (“IPO”) through to run our business. We devote December 31, 2006) of approxi - extraordinary efforts to find the mately 23.8% (assuming most talented people and offer reinvestment of all dividends), them the tools they need to approximately 33.6% in total make a significant improve - assets, approximately 34.5% in ment in the human condition. total market capitalization, and We develop the best environ - approximately 23.7% in funds ments for the best scientific from operations, demon - people and entities, which in strating one of the real estate turn enhances health and industry’s top growth rates. extends life for the inhabitants Other key financial metrics of our planet. included our total shareholder We are the Landlord and return (assuming reinvestment Developer of Choice to the Life of all dividends) from our IPO Science Industry ®, a coveted through December 31, 2006, leadership position that we which approximated 677%, intend to maintain. Our brand significantly outperforming the is powerful, relevant, impor - NAREIT Index which increased tant, and impactful to our life approximately 284%, the science constituency, whom Russell 2000 Index which we deeply respect and increased approximately 133%, consider an integral part of our and the S&P 500 Index which complete team. Recently, one increased approximately 94%. of our most important client These are truly remarkable tenant relationships, The Bill accomplishments achieved and Melinda Gates Founda - through challenging and tion, in referring to Alexandria varying economic cycles. stated, “Thanks for being such Our focus is clear, our a collaborative partner to the expertise and experience in Foundation.” Our mission to both the real estate and life continue to be the dominant science industries are unparal - real estate provider to the life leled, and our unique and science industry necessitates highly focused strategy care - Jerry M. Sudarsky constant communication and fully crafted and executed. Chairman of the Board coherence with all of our stake - During 2006, and continuously Joel S. Marcus holders. To uphold these vital every quarter since our IPO, Chief Executive Officer 14 Alexandria Real Estate Equities, Inc. Alexandria has reported partnering transactions among multinational pharmaceutical and State of New York. The East consistent, stable, and solid and between pharmaceutical companies and larger biotech - River Science Park sits on a growth in funds from opera - and biotechnology companies. nology companies showed an prime site along the East tions per share (diluted). This Medicare prescription appetite for the acquisition of River consisting of 4.5 acres growth has been driven by the drug coverage was introduced companies with promising comprising approximately successful day-to-day execu - for the first time in history, products and technologies. 1.1 million gross square feet. tion of our differentiated and our nation’s life science Several of Alexandria’s client The East River Science Park is strategy, multi-faceted busi - industry demonstrated another tenants were acquired by phar - destined to become the pre- ness model and highly efficient year of growth. Despite the maceutical companies at eminent life science center in strategic operating platform leveled-off National Institutes significant premiums last year, New York City. focused on dominating our key of Health’s funding for the including a $1.1 billion acquisi - life science cluster markets. industry now at a record tion of Sirna Therapeutics, Inc., Operational Review Our client tenant base is the annual pace of almost $29 by Merck & Co., Inc. The And Financial Highlights most exceptional and notable billion, the pharmaceutical industry observers anticipate Once again, and for every it has ever been with Novartis and biotechnology industries similar acquisition trends at quarter as a public company, AG, one of the world’s leading combined invested a record least for the next few years. our full-year growth in GAAP pharmaceutical companies, as $55.2 billion in research and net operating income for our our largest client tenant. The development activities in 2006, Technology Square @ MIT static pool of “same proper - strength and diversity of our representing an almost 8% In the summer of 2006, Alexan - ties” has been positive and client tenants, coupled with increase over the 2005 industry dria and The Massachusetts approximated 2.1%, and cash their average lease durations expenditures. This significant Institute o f Technology (“MIT”) net operating income for these in excess of 7 years, provide investment indicates the indus - formed a 90/10 joint venture properties grew approximately Alexandria with long-term tries’ fundamental stability, for the Technology Square @ 4.1%. These internal growth quality cash flow. These enabling them to continue MIT project comprising nearly metrics represent broad-based combined attributes should to discover, develop, and 1.2 million square feet of office solid performance in our enable continued growth commercialize new products and laboratory space situated markets. Contributing to this during both positive and to service the world’s growing immediately adjacent to the growth is the fact that approxi - challenging economic demands for safe and effective MIT campus on Main Street in mately 89% of our leases have environments. healthcare products. Today, Kendall Square, Cambridge. annual rental rate increases, During 2006, we raised more than 2,300 drug candi - This signature campus is generally with minimum our quarterly cash dividend dates are in clinical trials or at anchored by Novartis AG and annual increases approxi - per common share approxi - the Food and Drug Administra - MIT. Our strategic venture also mating three plus percent. mately 6%. This increase tion for review. provides significant upside due Rental rate increases on the reflects our policy to seek Indeed, in 2006, we to the redevelopment opportu - rollover of leases in our asset managed growth in dividends witnessed many key events nities of two key buildings on base which have been positive while retaining a significant that evidenced the pharmaceu - the seven building campus. every year as a publicly traded level of free
Load more

Recommended publications
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Bio-IT World Conference & Expo
    Featured Presentations by: Platinum Sponsors: Font: Optima Regular Colors: Dark Blue #003399 (CMYK 96, 69, 3, 0) Light Blue #6699CC (CMYK 62, 22, 3, 0) ENABlING TECHNOlOGy. Leveraging Data. TransformING mEDICINE. CONCURRENT TRACKS: KEYNOTE PRESENTATIONS BY: 1 IT Infrastructure — Hardware 2 IT Infrastructure — Software John Halamka, m.D., m.S., Gold Sponsors: CIO, Harvard Medical School 3 Bioinformatics and Next-Gen Data 4 Systems and Predictive Biology 5 Cheminformatics and ARTISTS IN DATA STORAGE Computer-Aided Modeling Christoph Westphal, m.D., Ph.D., eClinical Trials Technology CEO, Sirtris Pharmaceuticals; 6 Senior Vice President, Centre of 7 eHealth Solutions Excellence for External Drug Discovery, GlaxoSmithKline Deepak Singh, Ph.D., EVENT FEATURES: Business Development Manager, Access All Seven Tracks for One Price Amazon Web Services Network with 1,500+ Attendees Hear 100+ Technology and Scientific Presentations Bronze Sponsors: Attend Bio-IT World’s Best KEYNOTE PANEL: Practices Awards The Future of Personal Genomics Connect with Attendees Using CHI’s Intro-Net A special plenary panel discussion featuring: Participate in the Poster Competition James Heywood, Co-founder and Chairman, PatientsLikeMe See the Winners of the following Dan Vorhaus, J.D., M.A., Attorney, Robinson, Bradshaw & Hinson; 2010 Awards: Editor, Genomics Law Report Benjamin Franklin Dietrich Stephan, Ph.D., President & CEO, Ignite Institute Best of Show Kári Stefánsson, MD, Dr Med, Executive Chairman and President Best Practices of Research, deCODE genetics View Novel Technologies and Solutions in the Expansive Exhibit Hall Kevin Davies, Ph.D., Editor-in-Chief, Bio-IT World And Much More! And More... BIONETWORKS Corporate Support Sponsors Bio-ITWorldExpo.com Organized & Managed by: Official Publication: Cambridge Healthtech Institute 250 First Avenue, Suite 300, Needham, MA 02494 Phone: 781-972-5400 • Fax: 781-972-5425 • Toll-free in the U.S.
    [Show full text]
  • Reactive Oxygen Species Insufficiency (ROSI) As the Basis for Disease Allowance and Coexistence
    Reactive Oxygen Species Insufficiency (ROSI) as the Basis for Disease Allowance and Coexistence: Extraordinary Support for an Extraordinary Theory VOLUME I (One) BY PROF. HON. RANDOLPH M. HOWES, M.D., Ph.D. Orthomolecular Surgical Scientist and Biochemist Contents of volumes I through III: Volume I (One) Pages 1-530 of original: pp 501 Sections 1.0-1.9.0.4 Volume II (Two) Pages 531-1018 of original: pp 505 Sections 1.9.0.5-11.1.3 Volume III (Three) Pages 1019-1564 of original: pp 562 Sections 11.1.4-20.0.0 Unauthorized use of any of this material, without author permission, is prohibited by law. © 2008, Randolph M. Howes, M.D., Ph.D. Reactive Oxygen Species Insufficiency (ROSI) as the Basis for Disease Allowance and Coexistent: Extraordinary Support for an Extraordinary Theory Relationships between CANCER, ATHEROSCLEROSIS, DIABETES, OBESITY, HYPERTENSION, ARTHRITIS & CATARACTS (EMOD Insufficiency Syndrome of Howes) (EMODs) Electronically Modified Oxygen Derivatives THE HOWES SELECTIVE WORLD LIBRARY OF OXYGEN METABOLISM [The seventh in a series and a companion book to the following: #1. U.T.O.P.I.A. © 2004 Unified Theory of Oxygen Participation In Aerobiosis; #2. The Medical and Scientific Significance of Oxygen Free Radical Metabolism © 2005; #3. Hydrogen Peroxide Monograph 1: Scientific, Medical and Biochemical Overview & #4. Antioxidant Vitamins A, C, & E Monograph 2: Equivocal Scientific Studies, © 2006; #5. Cardiovascular Disease and Oxygen Free Radical Mythology, © 2006; #6. Diabetes and Oxygen Free Radical Sophistry, © 2006] A Selective World Literature Review Available at www.thepundit.com BY PROF. HON. RANDOLPH M. HOWES, M.D., Ph.D.
    [Show full text]
  • United States Securities and Exchange Commission Form
    Use these links to rapidly review the document TABLE OF CONTENTS Index to Consolidated Financial Statements of OvaScience, Inc. Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-54647 OVASCIENCE, INC. (Exact name of registrant as specified in its charter) Delaware 45-1472564 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification Number) 215 First Street, Suite 240 Cambridge, Massachusetts (Address of Principal Executive 02142 Offices) (Zip Code) Registrant's telephone number, including area code: (617) 500-2802 Securities registered pursuant to Section 12(b) of the Act: None Securities registered pursuant to Section 12(g) of the Act: Title of each class Common Stock, par value $0.001 per share Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. Yes o No Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • View Annual Report
    Use these links to rapidly review the document TABLE OF CONTENTS Verastem, Inc. (A development stage company) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3269467 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 215 First Street, Suite 440 Cambridge, Massachusetts (Address of principal executive 02142 offices) (Zip Code) Registrant's telephone number, including area code: (617) 252-9300 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Title of each class registered Common Stock, $0.0001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. o Yes No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o Yes No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • The Future of Personal Genomics
    SCHEDULE-AT-A-GLANCE KEYNOTE SPEAKERS: Tuesday, April 20, 2010 John Halamka, M.D., M.S., CIO, Harvard Medical School 7:00-8:00am Pre-Conference Registration and Morning Coffee John D. Halamka, M.D., M.S. is Chief Information Officer of Beth Israel Deaconess Medical Center, Chief Information Officer of Harvard Medical School, Chairman of the New England 8:00am-4:00pm Pre-Conference Workshops Healthcare Exchange Network (NEHEN), Chair of the US Healthcare Information Technology 2:00-6:00pm Main Conference Registration Standards Panel (HITSP), co-Chair of the HIT Standards Committee, and a practicing 4:00pm Keynote Presentation Emergency Physician. As Chief Information Officer of Beth Israel Deaconess Medical 5:00-7:00pm Welcome Reception in Exhibit Hall Center, he is responsible for all clinical, financial, administrative and academic information technology serving 3000 doctors, 14000 employees and two million patients. As Chief Wednesday, April 21, 2010 Information Officer of Harvard Medical School, he oversees all educational, research and 7:30am Registration and Morning Coffee administrative computing for 18000 faculty and 3000 students. As Chairman of NEHEN 8:20am Keynote Presentations & 2010 he oversees clinical and administrative data exchange in Massachusetts. As Chair of Benjamin Franklin Award HITSP/co-Chair of the HIT Standards Committee he coordinates the process of electronic 9:30am Exhibit Hall Opens standards harmonization among stakeholders nationwide. 9:30-10:50am Coffee Break, Exhibit and Dedicated Poster Viewing Christoph Westphal, M.D., Ph.D., CEO, Sirtris Pharmaceuticals; Senior Vice 10:50am-12:30pm Main Conference Tracks 1-7 President, Centre of Excellence for External Drug Discovery, GlaxoSmithKline 12:30-1:40pm Luncheon Presentation (Sponsorship Opportunity Available) Christoph Westphal, M.D., Ph.D., co-founded Sirtris Pharmaceuticals, Inc.
    [Show full text]
  • Pharmavoice 100 Honorees, Including Our Own Kara Dennis and Steve Smith!
    Celebration InspiredLEADERS By IMPACTING THE LIFE-SCIENCES INDUSTRY September 17, 2015 PHARMAVOICE 100 CELEBRATION 1 Celebrating Innovation and Inspiration in the Life Sciences Congratulations to this year’s PharmaVOICE 100 honorees, including our own Kara Dennis and Steve Smith! We commend PharmaVOICE for showcasing the outstanding work of industry thought leaders for over a decade. Thank you for fostering collaboration across the life sciences and for sharing innovative ideas and insights that are moving our industry forward. Steve Smith Kara Dennis Chief Patient Advocate Managing Director of mHealth [email protected] | mdsol.com | +1 866 515 6044 Celebration WELCOME LETTER he idea behind publication: The Forum for the Industry Executive PharmaVOICE — both — which is why this inaugural Celebration event is so Tmagazine and online — created a special and exciting. We have the opportunity to bring forum for leaders to Read. Think. together and recognize in person the men and women Participate. in the dynamic life-sciences — the PharmaVOICE 100 and Red Jacket honorees — industry. From molecule to market, who are impacting change throughout the life-sciences PharmaVOICE has been providing the industry and who inspire so many people every day. perspectives and insights of passionate We have enjoyed getting to know each and every one and committed thought leaders for of the honorees over the years, and we look forward to nearly 15 years. their inspired leadership for years to come. Taren Grom Editor, PharmaVOICE On the way to an industry trade On behalf of everyone at PharmaVOICE, I want to show, about three years after the thank all of our generous sponsors and attendees who made this event possible.
    [Show full text]
  • Schedule 14A
    QuickLinks -- Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material under §240.14a-12 Verastem, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ý No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: (2) Aggregate number of securities to which transaction applies: (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): (4) Proposed maximum aggregate value of transaction: (5) Total fee paid: o Fee paid previously with preliminary materials. o Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
    [Show full text]
  • Verastem, Inc. (Exact Name of Registrant As Specified in Its Charter)
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2011 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35403 Verastem, Inc. (Exact name of registrant as specified in its charter) Delaware 27-3269467 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 215 First Street, Suite 440 Cambridge, Massachusetts 02142 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (617) 252-9300 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which Title of each class registered Common Stock, $0.0001 par value NASDAQ Global Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. o Yes x No Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. o Yes x No Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]